Clinical Research & Study Design
Our research often draws on data from controlled clinical trials and observational naturalistic settings. Our work includes descriptive prevalence and incidence studies, as well as analytical comparative studies that evaluate temporal relationships and etiological associations. We have investigated drug safety and adverse events; patient-reported outcomes, such as quality of life, functional status, and treatment satisfaction; and clinical effectiveness, such as mortality, morbidity, response to treatment, risk factors analysis, disease recurrence, drug adjuncts and switches, medication compliance, and medical persistence.
Selected Examples of Our Work
- Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Faisal M, Duh MS. Impact of Adverse Events, Treatment Modifications, and Dose Intensity on Survival Among Patients with Advanced Renal Cell Carcinoma Treated with First-Line Sunitinib: A Medical Chart Review Across Ten Centers in Five European Countries. Cancer Medicine. 2014; 10.1002/cam4.302.
- Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ. Period Prevalence of Concomitant Psychotropic Medication Usage Among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder During 2009. Journal of Child and Adolescent Psychopharmacology. 2014; 24(5). 260–268.
- Chen L, Guerin A, Marynchenko M, Ionescu-Ittu R, Hiscock R, Nitulescu R, Chopra P, Hsu LI, Keir C, Wu EQ. Impact of Low-Grade Adverse Events (AEs) on Health-Related Quality of Life (HRQoL) in Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) from the ENESTnd Trial: 48-Month Follow-Up. Blood. 2013; 122(21), 4038–4038.